Heterozygous vs Homozygous MTHFR: What Your Result Actually Means

Your MTHFR report came back and it says one of these things: heterozygous, homozygous, or compound heterozygous. Possibly with a rather ominous-looking genotype code like C/T or T/T next to it.

These words describe a genuinely different biological situation in each case. But the difference between them matters far less to your health than the internet will tell you — and understanding why requires understanding what the words actually mean first.

The basic genetics, in sixty seconds

You have two copies of almost every gene: one inherited from each biological parent. MTHFR is no exception. So for any given position in the MTHFR gene, you have two readings — one on each chromosome copy.

That is the whole vocabulary. "Homo-" means same, "hetero-" means different. Homozygous means both copies match; heterozygous means they differ.

A word on terminology while we are here: "homozygous" on its own is ambiguous, because you can be homozygous for the normal version too. When a report or a website says "homozygous MTHFR," they almost always mean homozygous for the variant. It is sloppy shorthand, and it is worth being precise about.

The fourth category: compound heterozygous

This one confuses people, and reasonably so. Compound heterozygous means you carry two different variants, one on each chromosome copy. In MTHFR's case, that means one copy carries C677T and the other carries A1298C.

You are heterozygous for each variant individually. But because both copies of your gene are affected — just by different changes — the combined situation is described as compound heterozygous.

This is not exotic. Because of how C677T and A1298C sit on the chromosome, a combination of both variants is usually seen specifically in individuals who are compound heterozygotes in trans — that is, one variant on each copy. It is the normal, expected way to end up with both.

What each genotype does to enzyme activity

Here is where the biology becomes concrete. Reduced enzyme activity is the mechanism through which any of this could matter, so it is the right thing to compare.

Two things jump out of that table.

First: even the most affected common genotype — homozygous C677T — retains roughly a third of normal enzyme activity. This is not an enzyme knockout. It is a somewhat less efficient enzyme.

Second: the genotypes with the biggest effects are also the most common. Over a quarter of one major population group is homozygous C677T. If a 60–70% reduction in this enzyme's activity produced serious disease, that would be catastrophically visible in population health data. It is not.

The part that changes everything: folate status

Enzyme activity is only half the equation. The other half is substrate availability — how much folate is coming in for the enzyme to work with.

This is the single most under-reported fact in the entire MTHFR discourse. A reduced-activity enzyme with abundant substrate can often keep up perfectly well. The genotype only bites when folate is scarce.

MTHFR deficiency results in mildly elevated homocysteine levels especially in individuals who are also deficient in folate. That qualifier is doing enormous work.

So the practical implication of a "worse" genotype is not that you have a disease. It is that your folate intake matters slightly more to you than it does to someone with two normal copies. That is a nutrition observation, not a diagnosis.

Which genotypes does the ACMG consider clinically insignificant?

This is the question everyone actually wants answered, and the guideline answers it directly.

Let us be precise about what this list does and does not say.

Explicitly named as unlikely to be significant: C677T het, A1298C homozygous, and compound het. That covers a very large share of everyone who gets an MTHFR result.

Notably absent from that list: homozygous C677T. The guideline does not name it as insignificant. But it also does not recommend testing for it — the same guideline's headline conclusion is that MTHFR polymorphism testing has minimal clinical utility and should not be ordered as part of routine evaluation. The absence of homozygous C677T from the "insignificant" list is best read as scientific caution, not as a warning.

Framed as speculative: triple variant. If you carry one of these rare genotypes, that is a genuinely reasonable thing to discuss with a genetic counselor. But note the word the guideline itself chose.

What compound heterozygous does NOT mean

The compound heterozygous result gets marketed harder than any other MTHFR genotype, usually framed as a "double mutation" that compounds risk. Two things are worth separating.

There is legitimate research suggesting that compound heterozygosity for C677T and A1298C produces a more meaningful reduction in enzyme activity than either variant alone, with associated homocysteine elevation. That research exists and we are not going to pretend otherwise.

But the ACMG, having reviewed that literature, placed compound heterozygosity on its list of genotypes unlikely to be clinically significant. When a specialist professional body reviews the whole evidence base and reaches a different conclusion from individual studies within it, the guideline is the more reliable guide for a personal health decision. Individual studies are inputs to guidelines; they are not substitutes for them.

So what should you actually do with your result?

The honest answer is that your response should look nearly identical regardless of which of these genotypes you have.

1. Eat adequate folate. Leafy greens, legumes, citrus, fortified grains, liver. This is the lever. It matters slightly more if you carry variants, and it is good advice regardless.
2. If you want to know if your methylation is actually impaired, measure homocysteine. A homocysteine test costs very little and measures the real output of the system — integrating your genotype, your diet, your B12 status and your kidney function all at once. Genotype is one input. Homocysteine is the result.
3. If you are pregnant or planning pregnancy, take standard folic acid. Do not adjust the preventive dose based on MTHFR results — this is explicit guidance.
4. Do not build a supplement stack around a genotype. Especially not one that appears on the ACMG's "unlikely to be significant" list.
5. If you have a rare triple variant genotype or genuinely elevated homocysteine, see a genetic counselor. Those are the situations where professional input adds real value.

The bottom line

Heterozygous means one copy. Homozygous means two. Compound heterozygous means one of each of two different variants. Each represents a slightly different degree of reduced enzyme activity, and none of them — at the levels these common variants produce — constitutes a disease.

The word on your report describes real biology. It does not describe a diagnosis, and it should not be the foundation of a health protocol.